Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

This study tests a new type of cell therapy called CAR-T therapy — where a patient's own immune cells (T-cells) are taken out, genetically modified to attack cancer, and put back in — for people with lymphoma that has relapsed (come back) or stopped responding to standard treatments. This particular CAR-T therapy targets two proteins on lymphoma cells at once: CD20 and CD30, making it potentially more effective for hard-to-treat cases. **You may be eligible if...** - You are 14 to 69 years old with relapsed or refractory lymphoma - Your lymphoma has not responded to current standard treatments, including stem cell transplant if you had one - You have measurable lymphoma on a scan - Your blood counts and organ function (heart, lungs, kidneys, liver) meet minimum thresholds **You may NOT be eligible if...** - You have active or uncontrolled infection - You have serious heart, lung, liver, or kidney problems - You are pregnant or breastfeeding - You are currently receiving immunosuppressive drugs (like high-dose steroids) - You have significant autoimmune conditions Talk to your doctor to see if this trial is right for you.